Fortis Healthcare runs a network of 37 hospitals and diagnostics labs (Agilus) across 12 states, and heads into its Q2 FY 2026-2027 print with hospital margins under scrutiny after an ESOP charge and legal costs weighed on Q1. The key things this print will speak to are whether the FY27 guidance stack — 15%+ organic hospital revenue growth and 150-200 bps ex-ESOP margin expansion — stays intact, and how the ~Rs. 277 Cr Suguna acquisition and Rs. 2,233 Cr net debt shape the balance sheet.
| Results date | November 05, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 2,545 Cr (+17.5% YoY, +7.6% QoQ) |
| Previous quarter PAT | Rs. 273 Cr (+2.3% YoY), including a Rs. 9.5 Cr exceptional gain |
| Previous quarter EBITDA margin | 22.3% (21.1% including ESOP expenses of ~Rs. 31 Cr) |
| Net debt (latest quarter) | Rs. 2,233 Cr (1.01x EBITDA) as of Jun 30, 2026 |
| Market cap | Rs. 59,305.74 Cr |
| CMP | Rs. 785.55 |
The board of Fortis Healthcare meets on November 05, 2026, to approve un-audited standalone and consolidated results for the quarter and half-year ended September 30, 2026, and to alter the terms of 1,55,000 listed senior unsecured redeemable NCDs of Rs. 1,00,000 face value each (aggregate Rs. 1,550 Cr). The trading window is closed up to November 7, 2026.
The Q2 FY27 post-results analyst call is scheduled for November 6, 2026, at 11:00 am IST. A replay of the call will be available from November 6 to November 13, 2026.
The Q2 FY27 print will test whether Fortis' guidance stack survives its cost headwinds: management has reiterated 15%+ strictly-organic FY27 hospital revenue growth and 150-200 bps ex-ESOP margin expansion toward a 25% normalized hospital EBITDA margin by FY28, while the ESOP charge is guided at ~Rs. 40 Cr per quarter in FY27.
Q1FY27 showed the tension — hospital margin of 21.5% was down 60 bps vs Q4FY26, occupancy improved 0.7 pp QoQ to 68.7%, and ARPOB rose to Rs. 2.71 Cr — with new units dragging consolidated EBITDA margin by 0.4% before an expected swing to +1% as they mature.
The demand backdrop supports the revenue leg: health insurance premiums grew 21.5% YoY to Rs. 53,813 Cr in April-July FY27, feeding the insured/TPA channels that carry Fortis' tertiary-care book, and the prior-year base is easier because Q2FY26 was disrupted by Punjab flooding and an elongated monsoon.
The margin leg is the contested one — the CGHS rate revision effective October 13, 2025 is annualizing in the payor mix, but government-payor collection delays (a parliamentary panel flagged CGHS dues delayed up to 18 months) and the international-patient slowdown (11% growth in Q4FY26 vs 18-20% historically) remain live drags.
On the call, expect management to settle the conflicting pre-ESOP vs after-ESOP framing of the 25%-by-FY28 target, update bed-addition progress (100 of 500+ FY27 beds done, with FMRI's ~200 beds awaiting an occupancy certificate), and address the Daiichi Sankyo forensic audit, which the Supreme Court narrowed on September 29, 2026 with no liability, penalty or fine imposed on the company.
Performance vs Guidance Tracking: Management reiterated its guidance stack in Q1FY27 despite cost headwinds — here is what to verify against the Q2 print.
ESOP charge and margin bridge: The ESOP charge is the swing factor for sequential margin direction.
Balance sheet, NCDs and M&A funding: Post-quarter acquisitions and the NCD agenda put the debt trajectory in focus.
Litigation and legal cost run-rate: The Daiichi Sankyo matter has been partially contained but costs continue.
Management transition and promoter trajectory: Leadership changes and promoter-level plans frame the medium-term narrative.
BG Road runs at 55% occupancy against a regional average of 63-64%, which management attributes to intense local competition and a strategic shift away from government business. Management has targeted occupancy above 60% following brownfield expansions, citing better clinical talent and marketing as levers.
Management has said debt-to-EBITDA is manageable with room for more, and that a potential IHH equity infusion after the settled open offer could fund debt reduction or growth. Net debt stood at Rs. 2,233 Cr, or 1.01x EBITDA, at Jun 30, 2026.
Management has deferred value-unlocking alternatives for Agilus Diagnostics and says the current focus is operational profitability. No timeline has been offered.
The current forensic audit is being borne by Daiichi Sankyo per the court order, and management has said prior audit costs were 'not a substantial sum'. No liability, penalty or fine has been imposed on Fortis, which was neither a party to the original dispute nor a judgment debtor.
Consolidated revenue rose 17.5% YoY to Rs. 2,545 Cr in Q1FY27, with hospital revenue up 18.98% and diagnostics gross revenue up 10.2% YoY. Management has guided to 15%+ strictly-organic hospital revenue growth for FY27, with acquisitions treated as upside.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.